Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation

European Heart Journal

Volumn 35, Issue 8, 2014, Pages 517-523

  Ulimoen, Sara R ^a   Enger, Steve ^a   Pripp, Are Hugo ^b   Abdelnoor, Michael ^b   Arnesen, Harald ^c,d   Gjesdal, Knut ^c,d   Tveit, Arnljot ^a  

^a VESTRE VIKEN HOSPITAL TRUST   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

Atrial fibrillation; Exercise capacity; Natriuretic peptides; Rate control

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DILTIAZEM; METOPROLOL; VERAPAMIL;

ADULT; AGED; ARTICLE; BICYCLE ERGOMETER; BODY MASS; CARDIO PULMONARY EXERCISE TEST; CARDIOPULMONARY EXERCISE TEST; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; EXERCISE; EXERCISE TEST; FEMALE; FORCED EXPIRATORY VOLUME; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FUNCTION; HEART RATE; HUMAN; LUNG DIFFUSION CAPACITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PERMANENT ATRIAL FIBRILLATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY QUOTIENT; REST; UNSPECIFIED SIDE EFFECT; VERY ELDERLY;

ATRIAL FIBRILLATION; EXERCISE CAPACITY; NATRIURETIC PEPTIDES; RATE CONTROL;

ADRENERGIC BETA-ANTAGONISTS; AGED; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; CARBAZOLES; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DILTIAZEM; EXERCISE TOLERANCE; FEMALE; HUMANS; MALE; METOPROLOL; NATRIURETIC PEPTIDE, BRAIN; OXYGEN CONSUMPTION; PEPTIDE FRAGMENTS; PROPANOLAMINES; PROSPECTIVE STUDIES; VERAPAMIL;

EID: 84896691138     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht429     Document Type: Article

References (48)

1. Ariansen I, Gjesdal K, Abdelnoor M, Edvardsen E, Enger S, Tveit A. Quality of life, exercise capacity and comorbidity in old patients with permanent atrial fibrillation. J Atrial Fibrillation 2008;1:202-208.
2. Ostermaier RH, Lampert S, Dalla VL, Ravid S. The effect of atrial fibrillation and the ventricular rate control on exercise capacity. Clin Cardiol 1997;20:23-27.
3. Wozakowska-Kaplon B, Opolski G. Improvement in exercise performance after successful cardioversion in patients with persistent atrial fibrillation and symptoms of heart failure. Kardiol Pol 2003;59:213-223.
4. Pardaens K, Van CJ, Vanhaecke J, Fagard RH. Atrial fibrillation is associated with a lower exercise capacity in male chronic heart failure patients. Heart 1997; 78:564-568.
5. Knudsen CW, Omland T, Clopton P, Westheim A, Wu AH, Duc P, McCord J, Nowak RM, Hollander JE, Storrow AB, Abraham WT, McCullough PA, Maisel A. Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study. J Am Coll Cardiol 2005;46:838-844.
6. Bakowski D,Wozakowska-Kaplon B, Opolski G. The influence of left ventricle diastolic function on natriuretic peptides levels in patients with atrial fibrillation. Pacing Clin Electrophysiol 2009;32:745-752.
7. Kim WS, Park SH. Correlation between N-terminal Pro-brain natriuretic peptide and Doppler echocardiographic parameters of left ventricular filling pressure in atrial fibrillation. J Cardiovasc Ultrasound 2011;19:26-31.
8. Ulimoen SR, Enger S, Tveit A. Impact of atrial fibrillation on NT-proBNP levels in a 75-year-old population. Scand J Clin Lab Invest 2009;69:579-584.
9. Engelmann MD, Niemann L, Kanstrup IL, Skagen K, Godtfredsen J. Natriuretic peptide response to dynamic exercise in patients with atrial fibrillation. Int J Cardiol 2005;105:31-39.
10. Wozakowska-Kaplon B, Opolski G. Effects of exercise testing on natriuretic peptide secretion in patients with atrial fibrillation. Kardiol Pol 2009;67:254-261.
11. Duttaroy S, Thorell D, Karlsson L, Borjesson M. A single-bout of one-hour spinning exercise increases troponin T in healthy subjects. Scand Cardiovasc J 2012;46:2-6.
12. Bordbar S, Bigi MA, Aslani A, Rahimi E, Ahmadi N. Effect of endurance and strength exercise on release of brain natriuretic peptide. J Cardiovasc Dis Res 2012;3:22-25.
13. Asselbergs FW, van den Berg MP, Bakker SJ, Signorovitch JE, Hillege HL, van Gilst WH, van Veldhuisen DJ. N-terminal pro B-type natriuretic peptide levels predict newly detected atrial fibrillation in a population-based cohort. Neth Heart J 2008;16:73-78.
14. Wazni OM, Martin DO, Marrouche NF, Latif AA, Ziada K, Shaaraoui M, Almahameed S, Schweikert RA, Saliba WI, Gillinov AM, Tang WH, Mills RM, Francis GS, Young JB, Natale A. Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery. Circulation 2004; 110:124-127.
15. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De CR, De SJ, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for theManagement of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-2429.
16. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, Smith SC Jr, Priori SG, Estes NA III, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Jacobs AK, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Ohman EM, Stevenson WG, Tarkington LG, Yancy CW. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of theAmerican College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011;123: e269-e367.
17. LundstromT, Ryden L. Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. J Am Coll Cardiol 1990;16:86-90.
18. Kubac G, Malowany L. Functional capacity of patients with atrial fibrillation and controlled heart rate before and after cardioversion. Can J Cardiol 1992;8:941-946.
19. Ulimoen SR, Enger S, Carlson J, Platonov PG, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal K, Tveit A. Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol 2013;111:225-230.
20. Gibbons RJ, Balady GJ, Beasley JW, Bricker JT, Duvernoy WF, Froelicher VF, Mark DB, Marwick TH, McCallister BD, Thompson PD Jr, Winters WL, Yanowitz FG, Ritchie JL, Gibbons RJ, Cheitlin MD, Eagle KA, Gardner TJ, Garson A Jr, Lewis RP, O'Rourke RA, Ryan TJ. ACC/AHA Guidelines for Exercise Testing. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). J Am Coll Cardiol 1997;30:260-311.
21. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14:377-381.
22. Swank AM, Horton J, Fleg JL, Fonarow GC, Keteyian S, Goldberg L, Wolfel G, Handberg EM, Bensimhon D, Illiou MC, Vest M, Ewald G, Blackburn G, Leifer E, Cooper L, Kraus WE. Modest increase in peak VO2 is related to better clinical outcomes in chronic heart failure patients: results from heart failure and a controlled trial to investigate outcomes of exercise training. Circ Heart Fail 2012;5:579-585.
23. Schou M, Gustafsson F, Nielsen PH, Madsen LH, Kjaer A, Hildebrandt PR. Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. Eur J Heart Fail 2007;9:68-74.
24. Lang R, Klein HO, Di SE, Gefen J, Sareli P, Libhaber C, David D,Weiss E, Guerrero J, Kaplinsky E. Verapamil improves exercise capacity in chronic atrial fibrillation: double-blind crossover study. Am Heart J 1983;105:820-825.
25. Atwood JE, Myers JN, Sullivan MJ, Forbes SM, PewenWF, Froelicher VF. Diltiazem and exercise performance in patients with chronic atrial fibrillation. Chest 1988; 93:20-25.
26. Atwood JE, Sullivan M, Forbes S, Myers J, PewenW, Olson HG, Froelicher VF. Effect of beta-adrenergic blockade on exercise performance in patients with chronic atrial fibrillation. J Am Coll Cardiol 1987;10:314-320.
27. Baba O, Izuhara M, Kadota S, Mitsuoka H, Shioji K, Uegaito T, Mutsuo S, Matsuda M. Determinant factors of plasma B-type natriuretic peptide levels in patients with persistent nonvalvular atrial fibrillation and preserved left ventricular systolic function. J Cardiol 2009;54:402-408.
28. Lee SH, Choi S, Chung WJ, Byun YS, Ryu SK, Pyun WB, Rim SJ. Tissue Doppler index, E/E', and ischemic stroke in patients with atrial fibrillation and preserved left ventricular ejection fraction. J Neurol Sci 2008;271:148-152.
29. Lee SH, Jung JH, Choi SH, Lee N, Park WJ, Oh DJ, Rhim CY, Lee KH. Determinants of brain natriuretic peptide levels in patients with lone atrial fibrillation. Circ J 2006; 70:100-104.
30. Colin P, Ghaleh B, Hittinger L, Monnet X, Slama M, Giudicelli JF, Berdeaux A. Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise. Am J Physiol Heart Circ Physiol 2002;282:H672-H679.
31. Parker JD, Landzberg JS, Bittl JA, Mirsky I, Colucci WS. Effects of beta-adrenergic stimulation with dobutamine on isovolumic relaxation in the normal and failing human left ventricle. Circulation 1991;84:1040-1048.
32. Motoki H, Koyama J, TomitaT, AizawaK, Kasai H, KoshikawaM, IzawaA,Kumazaki S, Takahashi M, Ikeda U. Transient pseudorestrictive pattern of transmitral flow velocity curve in patients with paroxysmal atrial fibrillation. Echocardiography 2011; 28:289-297.
33. Yamada H, Donal E, Kim YJ, Agler DA, Zhang Y, Greenberg NL, Mazgalev TN, Thomas JD, Grimm RA. The pseudorestrictive pattern of transmitral Doppler flowpattern afterconversion of atrial fibrillation to sinus rhythm: is atrial or ventricular dysfunction to blame? J Am Soc Echocardiogr 2004;17:813-818.
34. Davis ME, Richards AM, Nicholls MG, Yandle TG, Frampton CM, Troughton RW. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 2006;113:977-985.
35. FungJW,YuCM,Yip G,Chan S, YandleTG, Richards AM, NichollsMG,Sanderson JE. Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol 2003;92:406-410.
36. Takeda Y, Fukutomi T, Suzuki S, Yamamoto K, Ogata M, Kondo H, Sugiura M, Shigeyama J, Itoh M. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. Am J Cardiol 2004;94:448-453.
37. Stanek B, Frey B, Hulsmann M, Berger R, Sturm B, Strametz-Juranek J, Bergler-Klein J, Moser P, Bojic A, Hartter E, Pacher R. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001;38:436-442.
38. Hara Y, Hamada M, Shigematsu Y, Ohtsuka T, Ogimoto A, Suzuki J, Higaki J. Effect of beta-blocker therapy in elderly patients with dilated cardiomyopathy. Circ J 2003;67: 826-829.
39. Olsson LG, Swedberg K, Cleland JG, Spark PA, Komajda M, Metra M, Torp-PedersenC, Remme WJ, Scherhag A, Poole-Wilson P. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a betablocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial. Eur J Heart Fail 2007;9:795-801.
40. Hung MJ, Cherng WJ,Wang CH, Kuo LT. Effects of verapamil in normal elderly individuals with left ventricular diastolic dysfunction. Echocardiography 2001;18: 123-129.
41. Inoue S, Murakami Y, Sano K, Katoh H, Shimada T. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 2000;6:92-96.
42. Daoud EG, Marcovitz P, Knight BP, Goyal R, Man KC, Strickberger SA, ArmstrongWF, Morady F. Short-term effect of atrial fibrillation on atrial contractile function in humans. Circulation 1999;99:3024-3027.
43. Hall C.NT-ProBNP: the mechanism behind the marker. J Card Fail 2005;11:S81-S83.
44. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL,Wann S.ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006;27:1979-2030.
45. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, van Veldhuisen DJ, van den Berg MP. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010;362:1363-1373.
46. Raatikainen MJ. Is verapamil a double-edged sword in rate control of paroxysmal atrial fibrillation? Heart Rhythm 2010;7:584-585.
47. Kuhlkamp V, Schirdewan A, Stangl K, Homberg M, Ploch M, Beck OA. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2000; 36:139-146.
48. Nergardh AK, Rosenqvist M, Nordlander R, Frick M. Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a randomized double-blind placebo-controlled study. Eur Heart J 2007;28:1351-1357.